Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 13Gastrointestinal 1

Conditions

Colorectal Neoplasms 1295Pancreatic Neoplasms 819Carcinoma, Hepatocellular 782Stomach Neoplasms 754Rectal Neoplasms 565Esophageal Neoplasms 452Colonic Neoplasms 414Esophageal Squamous Cell Carcinoma 277Neoplasm Metastasis 263Cholangiocarcinoma 251Liver Neoplasms 219Neoplasms 200Biliary Tract Neoplasms 179Adenocarcinoma Of Esophagus 139Gastrointestinal Stromal Tumors 108Gallbladder Neoplasms 96Adenocarcinoma 94Breast Neoplasms 91Gastrointestinal Neoplasms 89Carcinoma, Non-Small-Cell Lung 87Bile Duct Neoplasms 69Sarcoma 67Lung Neoplasms 64Ovarian Neoplasms 60Anus Neoplasms 59Melanoma 54Uterine Cervical Neoplasms 52Carcinoma 48Digestive System Neoplasms 45Prostatic Neoplasms 40

Interventions

pembrolizumab 1lenvatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Ovarian Diseases × Gastrointestinal × Clear all
NCT04519151 2023-06-08

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

Sheba Medical Center

Phase 2 Recruiting
24 enrolled
GastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Genital Neoplasms, Female, Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Stomach Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡